Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: Dopamine transporter function and cellular distribution in adulthood

Biochemical Pharmacology

Volumn 86, Issue 2, 2013, Pages 309-316

  Somkuwar, Sucharita S ^a,b   Darna, Mahesh ^a,b   Kantak, Kathleen M ^a,b   Dwoskin, Linda P ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Addiction; Attention deficit hyperactivity disorder; Cocaine; Dopamine transporter function; Methylphenidate; Spontaneously hypertensive rat

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ADOLESCENCE; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG BLOOD LEVEL; MALE; NONHUMAN; ORBITAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SYNAPTOSOME;

EID: 84884908313     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.04.013     Document Type: Article

References (81)

1. Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology 2009;57:579-89.
2. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry 2009;43:101-8.
3. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009;23(Suppl. 1):33-41.
4. Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 2005;57:1231-8. (Pubitemid 40798540)
5. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-23. (Pubitemid 40798551)
6. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002;114:975-9. (Pubitemid 35379243)
7. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1239-47. (Pubitemid 40798541)
8. Kantak KM, Singh T, Kerstetter KA, Dembro KA, Mutebi MM, Harvey RC, et al. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav Neurosci 2008;122:340-57. (Pubitemid 351672325)
9. Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Brain Res 1995;676:343-51.
10. Heal DJ, Smith SL, Kulkarni RS, Rowley HL. New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 2008;90:184-97.
11. Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI, et al. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 2010;167:1183-91.
12. Pandolfo P, Machado NJ, Kofalvi A, Takahashi RN, Cunha RA. Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 2012; epub ahead of print.
13. Sagvolden T, Johansen EB, Aase H, Russell VA. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/ impulsive and combined subtypes. Behav Brain Sci 2005;28:397-419. (Pubitemid 41440193)
14. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;104:277-86. (Pubitemid 14006365)
15. Andersen PH. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 1989;166:493-504. (Pubitemid 19195334)
16. Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: The role of methylphenidate. Curr Neuropharmacol 2008;6:322-8.
17. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attentiondeficit/ hyperactivity disorder. Biol Psychiatry 2005;57:1410-5. (Pubitemid 40798562)
18. Wilens TE, Biederman J, Does Mick E. ADHD affect the course of substance abuse. Findings from a sample of adults with and without ADHD. Am J Addict 1998;7:156-63.
19. Levin FR, Evans SM, Kleber HD. Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder. Psychiatr Serv 1999;50:1001-3. (Pubitemid 29365359)
20. Fischer M, Barkley RA. Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry 2003;64(Suppl. 11):19-23. (Pubitemid 37169645)
21. Winters KC, Lee S, Botzet A, Fahnhorst T, Realmuto GM, August GJ. A Prospective examination of the association of stimulant medication history and drug use outcomes among community samples of ADHD youths. J Child Adolesc Subst Abuse 2011;20:314-29.
22. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85. (Pubitemid 36071051)
23. Mannuzza S, Klein RG, Truong NL, Moulton 3rd JL, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008;165:604-9. (Pubitemid 351705337)
24. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attentiondeficit/ hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003;111:97-109. (Pubitemid 36071038)
25. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998;31:533-44.
26. Daws LC, Callaghan PD, Moron JA, Kahlig KM, Shippenberg TS, Javitch JA, et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 2002;290:1545-50. (Pubitemid 34687434)
27. Mandt BH, Zahniser NR. Low and high cocaine locomotor responding male Sprague-Dawley rats differ in rapid cocaine-induced regulation of striatal dopamine transporter function. Neuropharmacology 2010;58:605-12.
28. Huang X, Gu HH, Zhan CG. Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J Phys Chem B 2009;113:15057-66.
29. Winstanley CA, Olausson P, Taylor JR, Jentsch JD. Insight into the relationship between impulsivity and substance abuse from studies using animal models. Alcohol Clin Exp Res 2010;34:1306-18.
30. Groman SM, James AS, Jentsch JD. Poor response inhibition: at the nexus between substance abuse and attention deficit/hyperactivity disorder. Neurosci Biobehav Rev 2009;33:690-8.
31. Rubia K, Halari R, Christakou A, Taylor E. Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc Lond Ser B Biol Sci 2009;364:1919-31.
32. Burgess GC, Depue BE, Ruzic L, Willcutt EG, Du YP, Banich MT. Attentional control activation relates to working memory in attention-deficit/hyperactivity disorder. Biol Psychiatry 2010;67:632-40.
33. Posner J, Maia TV, Fair D, Peterson BS, Sonuga-Barke EJ, Nagel BJ. The attenuation of dysfunctional emotional processing with stimulant medication: an fMRI study of adolescents with ADHD. Psychiatry Res 2011;193:151-60.
34. Uylings HB, Groenewegen HJ, Kolb B. Do rats have a prefrontal cortex. Behav Brain Res 2003;146:3-17.
35. Beveridge TJ, Gill KE, Hanlon CA, Review Porrino LJ. Parallel studies of cocainerelated neural and cognitive impairment in humans and monkeys. Philos Trans R Soc Lond Ser B Biol Sci 2008;363:3257-66.
36. Goldstein RZ, Volkow ND, Wang GJ, Fowler JS, Rajaram S. Addiction changes orbitofrontal gyrus function: Involvement in response inhibition. Neuroreport 2001;12:2595-9. (Pubitemid 32682228)
37. Kaufman JN, Ross TJ, Stein EA, Garavan H. Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging. J Neurosci 2003;23:7839-43. (Pubitemid 37052351)
38. Maas LC, Lukas SE, Kaufman MJ, Weiss RD, Daniels SL, Rogers VW, et al. Functional magnetic resonance imaging of human brain activation during cueinduced cocaine craving. Am J Psychiatry 1998;155:124-6. (Pubitemid 28037560)
39. Brewer JA, Worhunsky PD, Carroll KM, Rounsaville BJ, Potenza MN. Pretreatment brain activation during stroop task is associated with outcomes in cocaine-dependent patients. Biol Psychiatry 2008;64:998-1004.
40. Grakalic I, Panlilio LV, Quiroz C, Schindler CW. Effects of orbitofrontal cortex lesions on cocaine self-administration. Neuroscience 2010;165:313-24.
41. Di Pietro NC, Black YD, Kantak KM. Context-dependent prefrontal cortex regulation of cocaine self-administration and reinstatement behaviors in rats. Eur J Neurosci 2006;24:3285-98. (Pubitemid 44952660)
42. Kantak KM, Yager LM, Brisotti MF. Impact of medial orbital cortex and medial subthalamic nucleus inactivation, individually and together, on the maintenance of cocaine self-administration behavior in rats. Behav Brain Res 2013;238:1-9.
43. Mashhoon Y, Wells AM, Kantak KM. Interaction of the rostral basolateral amygdala and prelimbic prefrontal cortex in regulating reinstatement of cocaine-seeking behavior. Pharmacol Biochem Behav 2010;96:347-53.
44. Harvey RC, Sen S, Deaciuc A, Dwoskin LP, Kantak KM. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology 2011;36:837-47.
45. Gilbert SJ, Burgess PW. Executive function. Curr Biol 2008;18:R110-4. (Pubitemid 351192314)
46. Lawrence NS, Jollant F, O'Daly O, Zelaya F, Phillips ML. Distinct roles of prefrontal cortical subregions in the Iowa Gambling Task. Cereb Cortex 2009;19:1134-43.
47. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:1111-20. (Pubitemid 44647216)
48. Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002;22:7264-71.
49. Doremus-Fitzwater TL, Varlinskaya EI, Spear LP. Motivational systems in adolescence: possible implications for age differences in substance abuse and other risk-taking behaviors. Brain Cogn 2010;72:114-23.
50. Spear L. Modeling adolescent development and alcohol use in animals. Alcohol Res Health 2000;24:115-23.
51. Marusich JA, Darna M, Charnigo RJ, Dwoskin LP, Bardo MT. A multivariate assessment of individual differences in sensation seeking and impulsivity as predictors of amphetamine self-administration and prefrontal dopamine function in rats. Exp Clin Psychopharmacol 2011;19:275-84.
52. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
53. Zhu J, Apparsundaram S, Bardo MT, Dwoskin LP. Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex. J Neurochem 2005;93:1434-43. (Pubitemid 40853266)
54. Salvatore MF, Apparsundaram S, Gerhardt GA. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 2003;24:1147-54. (Pubitemid 37487892)
55. Vadum AC, Rankin NO. Psychological research: methods for discovery and validation. Boston, MA: McGraw-Hill; 1998.
56. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. Springer series in statistics. New York: Springer; 2000. p. 1 online resource (xxii, 568 p.).
57. Sagvolden T, Johansen EB, Woien G, Walaas SI, Storm-Mathisen J, Bergersen LH, et al. The spontaneously hypertensive rat model of ADHD-the importance of selecting the appropriate reference strain. Neuropharmacology 2009;57:619-26.
58. van den Bergh FS, Bloemarts E, Chan JS, Groenink L, Olivier B, Oosting RS. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol Biochem Behav 2006;83:380-90. (Pubitemid 43736958)
59. Alsop B. Problems with spontaneously hypertensive rats (SHR) as a model of attention-deficit/hyperactivity disorder (AD/HD). J Neurosci Methods 2007;162:42-8. (Pubitemid 46527908)
60. Novick A, Yaroslavsky I, Tejani-Butt S. Strain differences in the expression of dopamine D1 receptors in Wistar-Kyoto (WKY) and Wistar rats. Life Sci 2008;83:74-8.
61. Yaroslavsky I, Colletti M, Jiao X, Tejani-Butt S. Strain differences in the distribution of dopamine (DA-2 and DA-3) receptor sites in rat brain. Life Sci 2006;79:772-6. (Pubitemid 43975127)
62. Jiao X, Pare WP, Tejani-Butt S. Strain differences in the distribution of dopamine transporter sites in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:913-9. (Pubitemid 37141379)
63. De La Garza 2nd R, Mahoney 3rd JJ. A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. Brain Res 2004;1021:209-18.
64. Li Q, Lu G, Antonio GE, Mak YT, Rudd JA, Fan M, et al. The usefulness of the spontaneously hypertensive rat to model attention-deficit/hyperactivity disorder (ADHD) may be explained by the differential expression of dopaminerelated genes in the brain. Neurochem Int 2007;50:848-57. (Pubitemid 46722647)
65. Miller EM, Pomerleau F, Huettl P, Russell VA, Gerhardt GA, Glaser PE. The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbens. Neuropharmacology 2012;63:1327-34.
66. Womersley JS, Hsieh JH, Kellaway LA, Gerhardt GA, Russell VA. Maternal separation affects dopamine transporter function in the spontaneously hypertensive rat: an in vivo electrochemical study. Behav Brain Funct 2011;7:49.
67. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 2007;34:1182-90. (Pubitemid 46394475)
68. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169:264-72.
69. Perry JL, Joseph JE, Jiang Y, Zimmerman RS, Kelly TH, Darna M, et al. Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions. Brain Res Rev 2011;65:124-49.
70. Schenk S, Horger BA, Peltier R, Shelton K. Supersensitivity to the reinforcing effects of cocaine following 6-hydroxydopamine lesions to the medial prefrontal cortex in rats. Brain Res 1991;543:227-35.
71. McGregor A, Baker G, Roberts DC. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on intravenous cocaine self-administration under a progressive ratio schedule of reinforcement. Pharmacol Biochem Behav 1996;53:5-9.
72. Zahniser NR, Sorkin A. Trafficking of dopamine transporters in psychostimulant actions. Semin Cell Dev Biol 2009;20:411-7.
73. Sorkina T, Hoover BR, Zahniser NR, Sorkin A. Constitutive and protein kinase Cinduced internalization of the dopamine transporter is mediated by a clathrindependent mechanism. Traffic 2005;6:157-70.
74. Adkins EM, Samuvel DJ, Fog JU, Eriksen J, Jayanthi LD, Vaegter CB, et al. Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 2007;46:10484-97. (Pubitemid 47417244)
75. Foster JD, Adkins SD, Lever JR, Vaughan RA. Phorbol ester induced traffickingindependent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem 2008;105:1683-99. (Pubitemid 351678491)
76. Zhu SJ, Kavanaugh MP, Sonders MS, Amara SG, Zahniser NR. Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997;282:1358-65. (Pubitemid 27408316)
77. Ramamoorthy S, Samuvel DJ, Balasubramaniam A, See RE, Jayanthi LD. Altered dopamine transporter function and phosphorylation following chronic cocaine self-administration and extinction in rats. Biochem Biophys Res Commun 2010;391:1517-21.
78. Samuvel DJ, Jayanthi LD, Manohar S, Kaliyaperumal K, See RE, Ramamoorthy S. Dysregulation of dopamine transporter trafficking and function after abstinence from cocaine self-administration in rats: evidence for differential regulation in caudate putamen and nucleus accumbens. J Pharmacol Exp Ther 2008;325:293-301. (Pubitemid 351439183)
79. Moritz AE, Foster JD, Gorentla BK, Mazei-Robison MS, Yang JW, Sitte HH, et al. Phosphorylation of dopamine transporter serine 7 modulates cocaine analog binding. J Biol Chem 2013;288:20-32.
80. American Academy of Pediatrics Committee on Children With Disabilities and Committee on Drugs. Medication for children with attentional disorders. Pediatrics 1996;98(2 Pt 1):301-4.
81. Harvey RC, Jordan CJ, Tassin DH, Moody KR, Dwoskin LP, Kantak KM. Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: Methylphenidate vs atomoxetine treatments. Behav Brain Res 2013;244:38-47.